Allergic asthma
Conditions
Interventions
investigational material(s)
Generic name etc : Omalizumab(Genetical Recombination)
INN of investigational material : Omalizumab(Genetical Recombination)
Therapeutic category code : 449 Other antiall
Sponsors
Novartis Pharma K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who completed the core study (IGE025B1301) and who in the investigator's clinical judgment could benefit from continuous treatment of the study drug.
Exclusion criteria
Exclusion criteria: 1.Patients who currently have diagnosed cancer, are currently being investigated for possible cancer or have any history of cancer. 2.Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are -women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner -women whose partners have been sterilized by vasectomy or other means -using a highly effective method of birth control agreeing on total abstinence and the investigator also judges that the age, career lifestyle or sexual orientation of the patient ensures compliance 3.With clinically significant uncontrolled systemic disease (eg: infection, hematological disease, renal, hepatic, coronary heart disease or other cardiovascular disease, cerebro-vascular, endocrinologic or gastrointestinal disease) after the treatment period of the core study 4.Patients with a history of major protocol violations during the core study and who are considered potentially unreliable as judged by the investigator at each site
Outcome results
None listed